Inhibition of the Progression of Skin Inflammation, Fibrosis, and Vascular Injury by Blockade of the CX3CL1/CX3CR1 Pathway in Experimental Mouse Models of Systemic Sclerosis

ConclusionAnti ‐CX3CL1 mAb therapy may be a novel approach for treating early skin fibrosis in inflammation ‐driven fibrotic skin disorders such as SSc.

Source: Arthritis and Rheumatology - September 10, 2019 Category: Rheumatology Authors: Vu H. Luong, Akira Utsunomiya, Takenao Chino, Le H. Doanh, Takashi Matsushita, Takashi Obara, Yoshikazu Kuboi, Naoto Ishii, Akihito Machinaga, Hideaki Ogasawara, Wataru Ikeda, Tetsu Kawano, Toshio Imai, Noritaka Oyama, Minoru Hasegawa Tags: Original Article Source Type: research